← All trials
NCT05328102
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Jan 31, 2027
- Completion date
- Jun 30, 2031
- First posted
- Apr 14, 2022
- Last posted
- May 6, 2022
- Enrollment
- 240
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- XencorLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.